Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic
syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or …

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The COG–…

PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …

Natural killer (NK) cells are innate lymphocytes important for early host defense against
infectious pathogens and surveillance against malignant transformation. Resting murine NK …

BACKGROUND: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and
current knowledge regarding survival in this disease is limited to small series of patients. …

7020 Background: Magrolimab is a monoclonal antibody blocking CD47, a “don’t eat me”
signal overexpressed on cancer cells such as acute myeloid leukemia (AML). This blockade …

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and have
been implicated in the pathogenesis of cancer. In this study, we applied next generation …

PURPOSE Magrolimab is a first-in-class humanized monoclonal antibody against cluster of
differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. …

Genomic transposable elements (TEs) comprise nearly half of the human genome. The
expression of TEs is considered potentially hazardous, as it can lead to insertional mutagenesis …

Background TP53 mutations, which are present in 5% to 10% of patients with acute myeloid
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …